- Home
- JRI vs CELC Comparison
JRI vs CELC Comparison
Compare JRI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRI
- CELC
- Stock Information
- Founded
- JRI 2012
- CELC 2011
- Country
- JRI United States
- CELC United States
- Employees
- JRI N/A
- CELC N/A
- Industry
- JRI Finance Companies
- CELC Medical Specialities
- Sector
- JRI Finance
- CELC Health Care
- Exchange
- JRI Nasdaq
- CELC Nasdaq
- Market Cap
- JRI N/A
- CELC 391.0M
- IPO Year
- JRI N/A
- CELC 2017
- Fundamental
- Price
- JRI $12.84
- CELC $8.85
- Analyst Decision
- JRI
- CELC Strong Buy
- Analyst Count
- JRI 0
- CELC 6
- Target Price
- JRI N/A
- CELC $30.17
- AVG Volume (30 Days)
- JRI 68.0K
- CELC 313.3K
- Earning Date
- JRI 01-01-0001
- CELC 05-14-2025
- Dividend Yield
- JRI 9.38%
- CELC N/A
- EPS Growth
- JRI N/A
- CELC N/A
- EPS
- JRI N/A
- CELC N/A
- Revenue
- JRI N/A
- CELC N/A
- Revenue This Year
- JRI N/A
- CELC N/A
- Revenue Next Year
- JRI N/A
- CELC N/A
- P/E Ratio
- JRI N/A
- CELC N/A
- Revenue Growth
- JRI N/A
- CELC N/A
- 52 Week Low
- JRI $9.70
- CELC $8.50
- 52 Week High
- JRI $12.12
- CELC $20.89
- Technical
- Relative Strength Index (RSI)
- JRI 46.06
- CELC 32.77
- Support Level
- JRI $12.81
- CELC $8.50
- Resistance Level
- JRI $13.05
- CELC $10.91
- Average True Range (ATR)
- JRI 0.16
- CELC 0.73
- MACD
- JRI -0.02
- CELC -0.10
- Stochastic Oscillator
- JRI 7.81
- CELC 13.11
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.